AIFA adds RANLUSPEC to simplified anti-VEGF monitoring form from 4 November
Italy's medicines agency says registry users can now select ranibizumab product RANLUSPEC in the simplified multi-drug form for intravitreal anti-VEGF treatments, covering four eye-disease indications.
The Italian Medicines Agency (AIFA) has told users of its Monitoring Registries that RANLUSPEC (ranibizumab) can be chosen in the simplified multi-drug monitoring form for intravitreal anti-VEGF medicines from 4 November 2026.
The change follows the entry into force of Determina Pres/1459/2026, for which a notice appeared in Italy's Official Gazette (Gazzetta Ufficiale) No. 256 of 3 November 2026. The determination is published as a PDF alongside the AIFA announcement.
RANLUSPEC can be selected for four indications: neovascular (wet) age-related macular degeneration; visual impairment due to diabetic macular oedema; visual impairment due to macular oedema secondary to retinal vein occlusion, either branch or central; and visual impairment due to choroidal neovascularisation.
The notice comes from AIFA's Monitoring Registries Office. It does not give further detail on reimbursement terms or on how the form operates beyond adding the product to the selection list.
As general context, AIFA's monitoring registries are web-based tools that track the prescribing of certain medicines under national reimbursement arrangements.
What it means for your team
- Prescribers and registry users should select RANLUSPEC in the simplified anti-VEGF intravitreal multi-drug form, rather than another route, for the four listed indications from 4 November 2026.
- Market-access teams for ranibizumab products should check Determina Pres/1459/2026 for the full terms behind the registry update.
- Hospital pharmacy and data-entry staff may need to update internal guidance so treatments are recorded in the correct monitoring form.
Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.
Market accessCompany releaseMedicare begins paying for Lucid's EsoGuard as PAVmed's Veris nears FDA 510(k) filing
Market accessOfficialDenmark updates Voltabak eye drop supply notice, with shortage expected to run to mid-May 2027
Market accessOfficialMethergin 0.2 mg/ml injection withdrawn from Danish market, DKMA reports
Market accessOfficialDenmark updates import window for estradiol 25 microgram patches in supply failure
Market accessOfficialDKMA updates Vivelle Dot 37.5 supply notice: shortage expected to last until end of December
Market accessOfficial